The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
This research study is a randomized controlled trial that will compare an exercise group to a control group on lower extremity function, CIPN, and inflammatory markers in ovarian or endometrial cancer patients undergoing first-line chemotherapy after surgery.
The names of the study interventions involved in this study are/is:
Aerobic and resistance exercise; virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom Attention control for 16 weeks, home-based stretching
The research study procedures include: screening for eligibility and study interventions including evaluations and follow up visits.
It is expected that about 30 people will take part in this research study.
Newly diagnosed patients with stages III-IV ovarian or endometrial cancer Receiving first-line carboplatin and paclitaxel chemotherapy after surgery ≥18 years, children under the age of 18 will be excluded due to rarity of disease Physician's clearance to participate in moderate-vigorous intensity exercise Able to read, write, and understand English Ability to understand and the willingness to sign an informed consent document Willing to undergo two venous blood draws for the study
Exclusion Criteria:
Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist Participants with uncontrolled intercurrent illness, as determined by the treating oncologist Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
